Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 231 to 240 of 1100 total matches.

Ramelteon (Rozerem) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 2005  (Issue 1221)
. with chronic insomnia (405) Data from manufacturer 10 Randomized, double-blind; Ramelteon 8 or 16 mg ...
Ramelteon (Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are classified as schedule IV drugs, ramelteon is not a controlled substance.
Med Lett Drugs Ther. 2005 Nov 7;47(1221):89-91 |  Show IntroductionHide Introduction

Cardiovascular Effects of Some Antidiabetic Drugs

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017  (Issue 1527)
cardiovascular outcomes data are not available to date for albiglutide (Tanzeum), dulaglutide (Trulicity ...
...
Med Lett Drugs Ther. 2017 Aug 14;59(1527):136-8 |  Show IntroductionHide Introduction

Platelet-Derived Growth Factor for Diabetic Ulcers

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 1998  (Issue 1031)
, but it is expensive, and published data are sparse. THE MEDICAL LETTER (ISSN 1523-2859) is published and printed ...
Becaplermin (be kap' ler min; Regranex - Ortho-McNeil), a 0.01% topical gel formulation of recombinant human platelet-derived growth factor (rhPDGF), was recently approved by the FDA for adjunctive treatment of diabetic ulcers of the lower extremities that extend subcutaneously or beyond and have an adequate blood supply. Endogenous platelet-derived growth factor increases proliferation of cells that repair wounds and form granulation tissue.
Med Lett Drugs Ther. 1998 Jul 17;40(1031):73-4 |  Show IntroductionHide Introduction

In Brief: Cardiovascular Safety of Varenicline (Chantix)

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011  (Issue 1371)
%) of 3308 taking placebo. This difference was statistically significant.4 Until more data become available ...
Varenicline (Chantix), which has been associated with neuropsychiatric symptoms such as agitation, depressed mood, changes in behavior and suicidal ideation, appears to be the most effective drug available for treatment of tobacco dependence.1 Recently, the FDA warned that varenicline may also increase the risk of cardiovascular adverse events in patients with cardiovascular disease.2 This warning was based on the results of a 12-week randomized trial in 714 smokers with stable cardiovascular disease. The drug was effective in helping patients stop smoking; long-term quit rates (at 52 weeks)...
Med Lett Drugs Ther. 2011 Aug 22;53(1371):65 |  Show IntroductionHide Introduction

In Brief: Propofol Revisited

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011  (Issue 1375)
. The mortality rate associated with brief use of propofol is so low that few data are available comparing ...
A reader has asked us to review the use of propofol (Diprivan, and others) as a sedative agent for brief procedures, such as colonoscopy.First marketed more than 20 years ago,1 propofol has a rapid onset of action (patients usually lose consciousness in less then one minute) and a short duration of action with a rapid recovery (3-5 minutes) that makes it highly suitable for brief ambulatory procedures. Propofol is now the most commonly used parenteral anesthetic in the US.2 The main problems with its use have been pain on injection and bacterial contamination, both related to its lipid...
Med Lett Drugs Ther. 2011 Oct 17;53(1375):84 |  Show IntroductionHide Introduction

In Brief: Icatibant (Firazyr) for Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2011  (Issue 1378)
:581. 4. Cost of a single dose according to most recent data (October 2011) from retail pharmacies ...
The FDA has approved icatibant (Firazyr – Shire), a selective bradykinin B2 receptor antagonist, for treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare autosomal dominant disorder (estimated prevalence 1:10,000-50,000) in which patients experience recurrent and frequently unpredictable attacks of angioedema lasting 2-5 days, typically involving the extremities, gastrointestinal tract, genitalia, face, oropharynx or larynx. Laryngeal edema may be life-threatening. HAE is usually caused by a mutation of the C1-inhibitor (C1-INH) gene. C1-INH is a serine proteinase...
Med Lett Drugs Ther. 2011 Nov 28;53(1378):96 |  Show IntroductionHide Introduction

In Brief: New Benzodiazepine Warnings

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020  (Issue 1610)
controlled substances. Postmarketing data and published literature have shown an increasing rate ...
The FDA now requires boxed warnings in the package inserts of benzodiazepines describing the potential for these drugs to be abused and misused and to cause addiction and physical dependence. Benzodiazepine labels have contained a boxed warning about a risk of serious drug interactions with opioids since 2016.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):175 |  Show IntroductionHide Introduction

In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million ...
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia that occurred following administration of the vaccine. In an April 14 emergency meeting, the Advisory Committee on Immunization Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million people in the US have received the Johnson & Johnson vaccine.
Med Lett Drugs Ther. 2021 May 3;63(1623):e1 |  Show IntroductionHide Introduction

COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
are no longer authorized for use as booster doses in any age group.1 No data on use of the bivalent vaccines ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children as young as 5 years old (Pfizer) or 6 years old (Moderna). The bivalent Pfizer vaccine had previously been authorized for use in persons ≥12 years old and the bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e1 |  Show IntroductionHide Introduction

Fluconazole

   
The Medical Letter on Drugs and Therapeutics • May 18, 1990  (Issue 818)
esophageal candidiasis, but the clinical response was faster with fluconazole. Available data are inadequate ...
Fluconazole (Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of candidiasis. Both cryptococcal meningitis and candidiasis occur frequently in patients with AIDS, organ transplants, or cancer.
Med Lett Drugs Ther. 1990 May 18;32(818):50-2 |  Show IntroductionHide Introduction